title: Increase in plasma ACTH induced by urethane is not a consequence of hyperosmolality.
abstract: Although anesthetic doses of urethane increase plasma levels of ACTH, the exact mechanism through which this occurs is unclear. We theorized that these increases might be a consequence of an increased systemic osmolality owing to the large doses of urethane usually employed. To evaluate this possibility, we measured plasma osmolality and ACTH in a total of six rats after graded infusions of urethane (N=3 rats) or equimolar amounts of mannitol (N=3 rats). Rats received infusions at 15 min intervals up to a cumulative dose equivalent to an anesthetic dose for urethane (1.4 g/kg). Blood samples (0.35 ml) were withdrawn at baseline and 10 min after each infusion. Urethane and mannitol produced significant and equivalent increases in plasma osmolality. However, only urethane evoked increases in plasma ACTH which were maximal (252+/-55 pg/ml from a baseline of 27+/-7 pg/ml) after a cumulative dose of 1 g/kg. Thus, increases in plasma ACTH seen after anesthetic doses of urethane are unlikely to be a consequence of its effect on plasma osmolality.
authors.affiliation: Department of Emergency Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA. dzaretsk@iupui.edu
authors.forename: Dmitry V
authors.initials: DV
authors.lastname: Zaretsky
authors.forename: Andrei I
authors.initials: AI
authors.lastname: Molosh
authors.forename: Maria V
authors.initials: MV
authors.lastname: Zaretskaia
authors.forename: Daniel E
authors.initials: DE
authors.lastname: Rusyniak
authors.forename: Joseph A
authors.initials: JA
authors.lastname: DiMicco
mesh_terms: D000324:Adrenocorticotropic Hormone / Q000097:blood*; D000704:Analysis of Variance; D018686:Anesthetics, Intravenous / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D001769:Blood / Q000187:drug effects* / Q000378:metabolism; D004234:Diuretics, Osmotic / Q000008:administration & dosage / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D007030:Hypothalamo-Hypophyseal System / Q000187:drug effects; D008297:Male; D008353:Mannitol / Q000008:administration & dosage / Q000494:pharmacology; D009994:Osmolar Concentration; D010913:Pituitary-Adrenal System / Q000187:drug effects; D011863:Radioimmunoassay; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D014520:Urethane / Q000008:administration & dosage / Q000494:pharmacology*
chemical_list: D018686:Anesthetics, Intravenous; D004234:Diuretics, Osmotic; D014520:Urethane; D008353:Mannitol; D000324:Adrenocorticotropic Hormone
references.citation: J Pharmacol Toxicol Methods. 2009 Jan-Feb;59(1):13-20
references.pmid: 18973819
references.citation: Anesth Analg. 2002 Feb;94(2):313-8, table of contents
references.pmid: 11812690
references.citation: Eur J Pharmacol. 1999 Aug 13;378(3):311-6
references.pmid: 10493107
references.citation: Brain Res. 1993 Dec 10;630(1-2):262-70
references.pmid: 8118692
references.citation: Brain Res Bull. 1993;32(6):567-72
references.pmid: 8221154
references.citation: Experientia. 1986 Feb 15;42(2):109-14
references.pmid: 2868911
references.citation: Neuroscience. 2010 Feb 3;165(3):976-83
references.pmid: 19896521
references.citation: Biochem Pharmacol. 1966 Jun;15(6):729-34
references.pmid: 5963904
references.citation: Neuroendocrinology. 1974;14(3):151-64
references.pmid: 4853652
references.citation: Neurosci Lett. 2006 Apr 24;397(3):291-6
references.pmid: 16406311
references.citation: Lab Anim. 2002 Apr;36(2):105-14
references.pmid: 11943074
references.citation: J Neuroendocrinol. 2001 Jul;13(7):596-607
references.pmid: 11442774
references.citation: Anesth Analg. 2002 Feb;94(2):241-2
references.pmid: 11812676
references.citation: Masui. 1993 Apr;42(4):552-6
references.pmid: 8391089
references.citation: Endocrinology. 1991 Jan;128(1):331-40
references.pmid: 1846102
references.citation: Neuroendocrinology. 1999 May;69(5):352-9
references.pmid: 10343176
references.citation: Stress. 2004 Jun;7(2):75-83
references.pmid: 15512850
references.citation: Regul Pept. 1986 Apr;14(2):125-32
references.pmid: 3012659
references.citation: Br J Pharmacol. 1988 Jul;94(3):647-52
references.pmid: 2846107
references.citation: Endocrinology. 1989 Jun;124(6):3102-8
references.pmid: 2542009
references.citation: Toxicol Appl Pharmacol. 1983 May;68(3):354-8
references.pmid: 6857669
references.citation: Arch Int Pharmacodyn Ther. 1975 Oct;217(2):257-75
references.pmid: 1190921
references.citation: Pharmacology. 1981;22(4):209-26
references.pmid: 7022489
references.citation: Experientia. 1986 Mar 15;42(3):292-7
references.pmid: 3007197
references.citation: Am J Physiol Heart Circ Physiol. 2009 Nov;297(5):H1661-72
references.pmid: 19749166
references.citation: Acta Endocrinol (Copenh). 1984 Jul;106(3):362-7
references.pmid: 6331038
references.citation: Jpn J Pharmacol. 1989 Apr;49(4):523-7
references.pmid: 2498560
references.citation: Am J Physiol Regul Integr Comp Physiol. 2009 Mar;296(3):R831-43
references.pmid: 19129373
references.citation: J Pharm Pharmacol. 1964 Sep;16:603-10
references.pmid: 14234871
references.citation: Experientia. 1986 May 15;42(5):531-7
references.pmid: 3519271
references.citation: Aust J Biol Sci. 1987;40(1):91-6
references.pmid: 3274655
references.citation: J Pharmacol Exp Ther. 1982 Nov;223(2):524-35
references.pmid: 6127404
references.citation: J Clin Endocrinol Metab. 1997 Apr;82(4):1243-7
references.pmid: 9100602
references.citation: Br J Pharmacol Chemother. 1965 Jun;24:752-8
references.pmid: 14340929